Your GLP-1 Is Doing More to Your Brain Than You Think

Your brain has a two-part system for reward, and most people only know about one of them.

The part everyone knows is pleasure, the actual good feeling you get when you eat something you love or have sex or hear a song that hits right. Neuroscientists call this "liking," and it runs on opioid signaling in specific brain regions.

The part most people do not think about is "wanting," which is the drive to pursue a reward before you get it. Wanting is what makes you reach for the snack, initiate sex, text someone back, get off the couch. It runs on dopamine, and it operates completely separately from liking.

This distinction matters more than almost anything else for understanding what GLP-1 drugs actually do to your brain.

GLP-1, or glucagon-like peptide-1, is a hormone your gut releases after you eat, and its job is to signal fullness to the brain. The drugs that mimic it, semaglutide, tirzepatide, retatrutide, were designed to tap into that fullness signal to reduce appetite. And they do that. But GLP-1 receptors are not only in the hypothalamus where hunger is regulated. They sit inside the brain's reward center, in a region called the ventral tegmental area, or VTA, which is the same circuit that drives motivation, craving, and desire for basically everything your brain considers worth pursuing.

Here is the specific mechanism. Inside the VTA, there are two relevant populations of neurons. Dopamine neurons, which fire to generate wanting, and GABA neurons, which act as a brake on those dopamine neurons. When GLP-1 receptors in the VTA are activated, they increase the firing of those GABA neurons, which suppresses dopamine neuron activity. You are not blocking dopamine directly. You are pressing the brake harder.

Research published in Science Advances in 2025 confirmed this circuit in detail, showing that endogenous GLP-1 signaling in the VTA increases GABAergic inhibition of dopamine neurons and attenuates reward-seeking behavior. This was demonstrated in the context of cocaine-seeking, which tells you something important: the dampening effect on wanting is not specific to food. It applies across the reward system.

And this is exactly why people on these drugs stop noticing they want things.

When the "liking" system is intact, nothing feels wrong. Sex still feels good when it happens. Food still tastes fine when you eat it. But the initiating behavior, the reaching, the craving, the pursuing, that goes quiet. There is no pain signal. There is no obvious deficit. The brain just stops generating the impulse to seek the reward in the first place.

A 2025 study in the Neurobiology of Disease and Treatment looked at semaglutide's effects on reward behavior directly, and found that it reduced reward collection behavior without diminishing the hedonic liking response, and actually showed enhanced VTA dopamine activity during the consummatory phase, meaning while the reward was happening. So the system is not broken. The on-ramp is just less steep.

This is also why the effect is so hard to attribute to the drug. If your desire for sex disappears but sex still feels good when it happens, and you also happen to be losing weight and feeling better about your body, and your energy levels are changing, the signal is buried under noise. The Obesity Pillars clinical review from 2026 calls this camouflage by competing positive effects, and it is probably the main reason this side effect is underreported.

But the dopamine brake is only one of two mechanisms that have been proposed.

GLP-1 drugs may also increase activity at something called the 5-HT2C receptor, which is a serotonin receptor that, when chronically activated, is one of the primary reasons SSRIs reduce sexual desire. That same Obesity Pillars review proposed that GLP-1 agonists likely upregulate 5-HT2C signaling, which would add a serotonergic layer to the dopaminergic suppression. This mechanism is theoretical at this point rather than directly confirmed in humans, but it fits with what clinicians are observing and with what is known about GLP-1 and serotonin crosstalk.

Two systems both suppressing wanting, neither one making anything feel wrong in the moment.

There is also evidence that the reward pathway effects extend well beyond sex and food. A randomized clinical trial published in JAMA Psychiatry in 2025 tested once-weekly semaglutide in 48 adults with alcohol use disorder, and found significant reductions in alcohol consumption, craving, and heavy drinking days compared to placebo. This was not a side effect study, it was the primary finding, and it confirms that the GLP-1 receptor system is doing broad motivational work across different types of desire and craving, not a narrow appetite effect.

The reversal question is straightforward. These drugs have half-lives of around a week, so after stopping, the drug clears in roughly two to three half-lives, with receptor signaling returning toward baseline within four to five weeks for most people. That timeline tracks with what people report subjectively, including the experience of drive returning suddenly and noticeably after stopping.

One null result worth noting: a 2024 double-blind crossover study testing dulaglutide in healthy eugonadal men over four weeks found no significant change in sexual function scores. Dulaglutide penetrates the central nervous system less effectively than semaglutide, and four weeks may be too short to detect gradual motivational changes, so this result does not contradict the mechanism, but it does suggest that drug-specific CNS penetration matters and that not all GLP-1 agonists will have identical effects on the brain.

The practical implication is simple. If you are on a GLP-1 drug and you have lost interest in things you used to care about, stopped initiating, stopped pursuing, stopped feeling the pull toward people or activities or goals, that is not a mood disorder and it is not a testosterone issue and it is not you becoming a different person. It is a drug interacting with a specific receptor in a specific region of the brain that controls the generation of desire itself.

The wanting system and the liking system are separate, and GLP-1 drugs are touching the one that does not announce itself when it goes quiet.

---

References

1. Merkel R, Thapa N, Engel L, et al. 2025. An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Science Advances, 119, eadr5051. Finding: GLP-1 receptor activation in the VTA increases GABA neuron firing, which suppresses dopamine neuron activity and reduces reward-seeking behavior. Source
2. Hurst K, et al. 2025. GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neurobiology of Disease and Treatment. Finding: Semaglutide reduced reward collection but did not diminish hedonic "liking" response, and actually enhanced VTA dopamine activity during consummatory phase. Source
3. Gelfand SG, Tveit RL, Simon JA. 2026. Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it. Obesity Pillars, 17, 100233. Finding: GLP-1 agonists likely decrease sexual desire via 5-HT2C serotonergic upregulation same mechanism as SSRIs, but this is camouflaged by competing positive effects of weight loss. Source
4. Hendershot CS, et al. 2025. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 824, 395-405. Finding: Semaglutide reduced alcohol consumption, craving, and heavy drinking days in a Phase 2 RCT n=48, confirming reward pathway modulation extends beyond appetite. Source
5. Jalleh RJ, et al. 2024. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. eBioMedicine, 107. Finding: 4-week dulaglutide in healthy eugonadal men showed no change in sexual function scores null result, but short duration and weaker CNS penetration than semaglutide. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness